Saara Kares, Olga Veijalainen, Ivana Kholová, Mika Tirkkonen, Risto Vuento, Heini Huhtala, Veronica Tuimala, Johanna Mäenpää, Paula Kujala
Since 2012, testing high risk (HR)HPV has been used as the primary screening test for women ≥35 years attending the organised cervical cancer screening programme in the city of Tampere. We evaluated the contribution of HPV16/18 genotyping. Data from 2012 and 2013, and the follow up samples in 2013 and 2014, respectively were analysed. Abbott RealTime High Risk HPV test detecting 14 HRHPV genotypes combined with concurrent genotyping for HPV16 and HPV18 was used. HPV was positive in 794 samples out of 11,346 HPV tested women (7%)...
August 12, 2019: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica